| Incidence of fatal adverse drug reactions: a population based study K Wester, AK Jönsson, O Spigset, H Druid, S Hägg British journal of clinical pharmacology 65 (4), 573-579, 2008 | 475 | 2008 |
| Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions–a meta-analysis KM Hakkarainen, K Hedna, M Petzold, S Hägg PloS one 7 (3), e33236, 2012 | 397 | 2012 |
| Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications S Hagg, L Joelsson, T Mjorndal, O Spigset, G Oja, R Dahlqvist Journal of Clinical Psychiatry 59 (6), 294-299, 1998 | 347 | 1998 |
| Adverse drug reactions as a cause for admissions to a department of internal medicine T Mjörndal, MD Boman, S Hägg, M Bäckström, BE Wiholm, A Wahlin, ... Pharmacoepidemiology and drug safety 11 (1), 65-72, 2002 | 317 | 2002 |
| High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia S Hägg, Y Lindblom, T Mjörndal, R Adolfsson International clinical psychopharmacology 21 (2), 93-98, 2006 | 230 | 2006 |
| Association of venous thromboembolism and clozapine S Hägg, O Spigset, TG Söderström The Lancet 355 (9210), 1155-1156, 2000 | 213 | 2000 |
| Glucose intolerance with atypical antipsychotics K Hedenmalm, S Hägg, M Ståhl, Ö Mortimer, O Spigset Drug safety 25, 1107-1116, 2002 | 195 | 2002 |
| Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers S Hägg, O Spigset, R Dahlqvist British journal of clinical pharmacology 51 (2), 169-173, 2001 | 195 | 2001 |
| Myocarditis related to clozapine treatment S Hägg, O Spigset, AB BAHons, TG Söderström Journal of clinical psychopharmacology 21 (4), 382-388, 2001 | 173 | 2001 |
| Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study K Hedna, KM Hakkarainen, H Gyllensten, AK Jönsson, M Petzold, S Hägg European journal of clinical pharmacology 71, 1525-1533, 2015 | 172 | 2015 |
| Antipsychotic-induced venous thromboembolism: a review of the evidence S Hägg, O Spigset CNS drugs 16, 765-776, 2002 | 160 | 2002 |
| Analgesics and breast-feeding: safety considerations O Spigset, S Hägg Paediatric drugs 2, 223-238, 2000 | 153 | 2000 |
| Fatal unintentional intoxications with tramadol during 1995–2005 M Tjäderborn, AK Jönsson, S Hägg, J Ahlner Forensic science international 173 (2-3), 107-111, 2007 | 152 | 2007 |
| Excretion of paroxetine into breast milk R Ohman, S Hagg, L Carleborg, O Spigset Journal of Clinical Psychiatry 60 (8), 519-523, 1999 | 122 | 1999 |
| Drug‐induced torsades de pointes: a review of the Swedish pharmacovigilance database C Åström‐Lilja, JM Odeberg, E Ekman, S Hägg Pharmacoepidemiology and drug safety 17 (6), 587-592, 2008 | 118 | 2008 |
| Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics S Hagg, S Soderberg, B Ahren, T Olsson, T Mjorndal Journal of Clinical Psychiatry 62 (11), 843-848, 2001 | 117 | 2001 |
| Prevalence, nature and potential preventability of adverse drug events–a population‐based medical record study of 4970 adults KM Hakkarainen, H Gyllensten, AK Jönsson, K Andersson Sundell, ... British journal of clinical pharmacology 78 (1), 170-183, 2014 | 105 | 2014 |
| Effect of caffeine on clozapine pharmacokinetics in healthy volunteers S Hägg, O Spigset, T Mjörndal, R Dahlqvist British journal of clinical pharmacology 49 (1), 59-63, 2000 | 105 | 2000 |
| Risk of venous thromboembolism due to antipsychotic drug therapy S Hägg, AK Jönsson, O Spigset Expert opinion on drug safety 8 (5), 537-547, 2009 | 103 | 2009 |
| Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden I Jacobsson, AK Jönsson, B Gerdén, S Hägg Pharmacoepidemiology and drug safety 18 (11), 1039-1047, 2009 | 102 | 2009 |
Max Petzoldprofessor i biostatistik, Göteborgs universitetVerified email at gu.se
